This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bavarian Nordic To Host Congresswoman Anna Eshoo For Discussion On Innovative Public-Private Partnerships In Cancer And Biodefense

MOUNTAIN VIEW, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Nasdaq:BAVA) announced today that the Company will be hosting Congresswoman Anna Eshoo (D-CA) and David Gollaher, President & CEO of the California Healthcare Institute at the corporate headquarters for its Bavarian Nordic ImmunoTherapeutics subsidiary in Mountain View, CA on February 21, 2013. During the visit, Representative Eshoo and Mr. Gollaher will meet with management to discuss the impact of recently passed legislation as well as the benefits of innovative public-private partnerships in cancer and biodefense.

Representative Eshoo is a lead sponsor of the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 as well as the Recalcitrant Cancer Research Act. The Recalcitrant Cancer Research Act was signed into law by President Obama as a part of the National Defense Authorization Act on January 3, 2013.  The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 is expected to be signed into law in the coming weeks.

"We're honored that Representative Eshoo will visit Bavarian Nordic to learn more about the opportunities and challenges facing an entrepreneurial immunotherapy company," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S. "We applaud her efforts to introduce legislation that encourages the development of early detection methods and better treatment options to improve cancer outcomes as well as medical countermeasures and are confident that such efforts will promote the continued growth of the life science industry and get innovations to patients faster."

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC(R), a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC(R) has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE(R), a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit

Contacts: Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 James Breitmeyer, Division President Cancer Vaccines. Phone +1-650-213-4968

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs